Stockscreener 앱 받기
2.6907
8.40%
0.1907
전일 마감가:
$2.50
열려 있는:
$2.42
하루 거래량:
77,971
Relative Volume:
0.07
시가총액:
$3.79M
수익:
-
순이익/손실:
$-9.32M
주가수익비율:
-3.7371
EPS:
-0.72
순현금흐름:
$-7.30M
1주 성능:
+21.52%
1개월 성능:
+26.64%
6개월 성능:
-53.73%
1년 성능:
-94.97%
1일 변동 폭
$2.36
$2.73
1주일 범위
$1.85
$2.73
52주 변동 폭
$1.835
$71.85
Tharimmune Inc Stock (THAR) Company Profile
명칭
Tharimmune Inc
전화
302-743-2995
주소
1200 ROUTE 22 EAST, BRIDGEWATER
THAR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| THAR | 2.71 | 3.79M | 0 | -9.32M | -7.30M | -0.72 |
| VRTX | 450.67 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.00 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 590.18 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.51 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 107.00 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Tharimmune Inc 주식(THAR)의 최신 뉴스
What's Going On With Tharimmune Shares Monday? - Benzinga
Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts
Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India
Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada
Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com Canada
What's Going On With Tharimmune Shares Wednesday? - MSN
Tharimmune set to receive European patent for cancer therapy tech - Investing.com
Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan
Tharimmune Announces Upcoming Conference Presentations - StockTitan
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN
United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN
S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN
New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
S&P 500 Total Return (TCU24) Quote - The Globe and Mail
Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR
Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph
Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks
Tharimmune secures EMA feedback on pruritus drug trial - Investing.com
Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan
TH104 trial shows promise for liver disease-related itch relief By Investing.com - Investing.com South Africa
TH104 trial shows promise for liver disease-related itch relief - Investing.com
Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - TipRanks
Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Milton Daily Standard
Tharimmune CEO Randy Milby buys $5.2k in company stock - Investing.com India
Tharimmune CEO Randy Milby buys $5.2k in company stock By Investing.com - Investing.com Australia
Tharimmune COO acquires $9,650 in company stock - Investing.com
Tharimmune COO acquires $9,650 in company stock By Investing.com - Investing.com UK
Biohaven aims to raise $250M; Activist investor’s stake in Galapagos exceeds 10% - Endpoints News
Tharimmune Announces Intent to Acquire Intract Pharma - TipRanks
Tharimmune signs nonbinding LOI to merge with Intract Pharma - TipRanks
Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - StockTitan
Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com India
Tharimmune Expands Immunology Pipeline with Intract License - TipRanks
Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan
Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World
Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3
Tharimmune adds David Clarke as Strategic Advisor - Investing.com
Tharimmune launches new website amid continuing discussions wtih FDA - TipRanks
Tharimmune Inc (THAR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):